Other studies using less selective PI3K/AKT inhibitors (wortmannin and LY294002) than those used here have shown efficacy in animal models of oesophageal cancer in combination with standard chemotherapies 5-Fu and cisplatin [36]. The gene discussed is AKT1; the disease is carcinoma of esophagus.